{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-157095","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2025-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.066705+00:00","generated_at":"2026-05-18T08:55:07.285756+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1","bullets":["Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.","Independent DSMB reviewed all six Cohort 1 subjects and recommended continuation of enrollment.","Enrollment of Cohort 2 expected to begin in Q4 2025 following positive DSMB recommendation.","Additional clinical study updates for Cohort 1 subjects planned for Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-157095","json":"https://secwatch.observer/filing/0001193125-25-157095.json","markdown":"https://secwatch.observer/filing/0001193125-25-157095.md","text":"https://secwatch.observer/filing/0001193125-25-157095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/0001193125-25-157095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312525157095/d96075d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-18T08:55:07.285756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}